Previous close | 57.91 |
Open | 57.08 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 56.55 - 57.25 |
52-week range | 51.78 - 86.31 |
Volume | |
Avg. volume | 82,881 |
Market cap | 42.185B |
Beta (5Y monthly) | 0.59 |
PE ratio (TTM) | 14.01 |
EPS (TTM) | 4.05 |
Earnings date | N/A |
Forward dividend & yield | 0.30 (0.53%) |
Ex-dividend date | 09 May 2022 |
1y target est | N/A |
(Reuters) -Swiss drug contract manufacturer Lonza said core earnings gained 20.7% in 2021, shored up by demand for the substances it supplies for new mRNA COVID-19 vaccines. Full-year core earnings before interest, tax, depreciation and amortisation (EBITDA) rose to 1.67 billion Swiss francs ($1.82 billion), up from 1.38 billion a year earlier, it said in a statement on Wednesday. For this year, Lonza predicted "low to mid-teens" sales growth, when excluding currency swings, as well as core EBITDA margin improvement from 30.8% in 2021.
In this Motley Fool Live video recorded on Nov. 3, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether investors should have Lonza on their watchlists. Keith Speights: Brian, one final topic before we get to questions.
By Dhirendra Tripathi